Category
Biotech & Pharma press releases
66 releases
Abbott launches whole-genome sequencing Oncodetect® molecular residual disease (MRD) test to detect traces of cancer during and after treatment
Powered by whole-genome sequencing and MAESTRO* technology, the next-generation Oncodetect test takes a distinct approach to MRD, tracking up to…
ESMO 2026: Key Findings for Cancer Care and Drug Development, Upcoming Webinar Hosted by Xtalks
In this free webinar, learn how major findings from ESMO 2026 could influence cancer treatment and oncology drug development. The featured speakers…
Anixa Biosciences Announces Completion of Treatment of Fifth Cohort in its Ovarian Cancer CAR-T Clinical Trial
First patient in fifth cohort exhibiting stable disease 90 days after treatment Multiple patients surviving more than one year, including one beyond…
Insilico Medicine Reports 40% ORR at 130 mg for Pan-TEAD Inhibitor ISM6331 Designed Using Generative AI in Heavily Pretreated Mesothelioma at ESMO 2026
Insilico Medicine ("Insilico", HKEX: 3696), a clinical-stage generative AI–driven drug discovery company, today announced promising first-in-human…
Vantive Announces Expansion of HomeAdvantage and Highlights New Evidence to Advance Home Dialysis During Kidney Week
Vantive plans to expand its HomeAdvantage offering with the next-generation Avira automated peritoneal dialysis cycler, which is progressing through…
Peer Reviewed Paper Calls for Stronger Safety Standards for Modified mRNA Vaccines
COVID-19 experience raises questions about manufacturing, biological persistence and long-term safety OCALA, Fla., Oct. 26, 2026 — Gerry A. Quinn,…
BioMarin to Host Third Quarter 2026 Financial Results Conference Call and Webcast on Monday, November 2, 2026, at 4:30pm ET
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Alexander Hardy, President and Chief Executive Officer of BioMarin, will host a…
Aurora Cannabis Announces the Alberta Securities Commission has dismissed Curaleaf's Application and ruled in favour of the Company's At-the-Market Program
NASDAQ | TSX: ACB Alberta Securities Commission dismisses Curaleaf's application concerning Aurora's ATM program. Curaleaf's unsuccessful application…
Oruka Therapeutics Announces Positive Week 16 Results for ORKA-001 from the Ongoing EVERLAST-B Trial in Moderate-to-Severe Psoriasis
61% PASI 100 and 86% PASI 90 in the ORKA-001 high-dose (600 mg) group, highly similar to EVERLAST-A
Azitra, Inc. Announces Revitalizing Results from Ex Vivo Study of ATR-COSF Demonstrating Ability to Reduce Fine Lines and Improve Elasticity in Human Skin
ATR-COSF uses a supernatant based formulation containing an active recombinant human domain of the protein, filaggrin. Ex vivo data in two models of…
Former FDA Head Steve Hahn Joins BreakBio, a Personalized Cancer Drug Company, as Advisor
BreakBio, a biotech company developing personalized drugs for cancer, today announced that Stephen M. Hahn, M.D., former Commissioner of the U.S.…
Beyond ctDNA: EVPs and the Future of Early Cancer Detection, Upcoming Webinar Hosted by Xtalks
In this free webinar, explore the potential of extracellular vesicles and particles (EVPs) as liquid biopsy analytes for early cancer detection.…
Acurex Biosciences Receives U.S. Composition-of-Matter Patent for CU-00048, a Potential Best-in-Class T-Type Calcium Channel Antagonist for Essential Tremor
Patent protects CU-00048 into 2042 as T-type calcium channel antagonists near their first FDA decision in Essential Tremor SAN CARLOS, Calif., Oct.…
Acurx Pharmaceuticals to Discuss Third Quarter 2026 Financial Results on November 12, 2026 Conference Call and Provide Business Update
Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of antibiotics…
Neurocrine Biosciences Presents New Analysis Establishing Benchmark for Clinically Meaningful Change in Overall Health Reported by Patients with Tardive Dyskinesia
New analysis establishes a 6-point increase on the EQ Visual Analogue Scale as a threshold for clinically meaningful change in overall health ratings…
TJ Biopharma Doses First Patient in Phase 1 Trial of TJ-C64B, a CLDN6x4-1BB Bispecific Antibody for CLDN6-Positive Solid Tumors
- TJ-C64B is an internally developed CLDN6 × 4-1BB bispecific antibody for which TJ Biopharma retains global rights, and is among the leading…
Advancing Diabetes Clinical Trials Through Integrated Technology and Operational Oversight, Upcoming Webinar Hosted by Xtalks
In this free webinar, learn how integrated technology and coordinated operational oversight can support diabetes clinical trial execution. The…
Galderma launches ALASTIN Restorative Eye Complex with TriHex+™, bringing new science-backed innovation to the entire eye area
Restorative Eye Complex is now formulated with TriHex+™, which pairs ALASTIN's TriHex Technology® to support the body's natural processes for…
Evogene to Participate in Upcoming BIO-Europe in Germany and Drug Discovery Chemistry Europe in Spain
Company to Attend BIO-Europe in Cologne, Germany, and Present a Scientific Poster at Drug Discovery Chemistry Europe in Barcelona, Spain REHOVOT,…